Vanguard reports 0 AVXL shares after internal realignment (AVXL)

Rhea-AI Filing Summary

Anavex Life Sciences Corp ownership filing shows 0 shares beneficially owned by The Vanguard Group as amended. The filing explains an internal realignment within Vanguard that led certain subsidiaries to report separately in reliance on SEC Release No. 34-39538, and states Vanguard reports no beneficial ownership in this class.

Insights

Institutional Ownership Analyst

Vanguard reports zero beneficial ownership following internal reorganization.

The amendment documents that The Vanguard Group reports 0 shares and 0% ownership of Anavex common stock. It cites SEC Release No. 34-39538 to explain disaggregation of holdings after an internal realignment effective January 12, 2026.

Cash-flow treatment and any selling intentions by underlying accounts are not described; subsequent filings from Vanguard or the underlying funds could show changes in reported ownership.

Corporate Governance Specialist

Administrative amendment clarifies reporting structure, not a market action.

The statement is procedural: subsidiaries or divisions will report separately and Vanguard no longer claims beneficial ownership over those holdings. The form lists address and officer signature and records 0 shares beneficially owned as of the amendment.

This is a disclosure of reporting status; it does not itself indicate purchases, sales, or control changes in Anavex.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Anavex Life Sciences Corp

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Anavex Life Sciences Corp
(b)	Address of issuer's principal executive offices: 51 West 52nd Street, 7th Floor, New York, NY, 10019
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd.,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	03/26/2026

FAQ

What does The Vanguard Group report for AVXL ownership?

The filing states The Vanguard Group beneficially owns 0 shares of Anavex common stock, representing 0% of the class. The amendment clarifies reporting after an internal realignment and cites SEC Release No. 34-39538 for disaggregation of subsidiary holdings.

Why did Vanguard change its reporting for AVXL?

Vanguard describes an internal realignment effective January 12, 2026 that resulted in subsidiaries reporting separately. The amendment relies on SEC Release No. 34-39538 to justify disaggregated reporting and states Vanguard no longer deems itself the beneficial owner of those subsidiary-held securities.

Does this Schedule 13G/A indicate Vanguard sold AVXL shares?

No. The amendment is an ownership disclosure showing 0 shares beneficially owned and explains a reporting change; it does not describe any sale, purchase, or proceeds. The filing records reporting structure adjustments rather than transactional activity.

Who signed the amendment for Vanguard on the AVXL filing?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026. The filing lists Vanguard's principal address as 100 Vanguard Blvd., Malvern, PA and Anavex's principal office address in New York.

Does the filing identify any person with voting or dispositive power for AVXL?

The Schedule 13G/A lists all voting and dispositive powers as 0: sole and shared voting power and sole and shared dispositive power are all reported as 0. No other person is identified as holding more than 5% of the class in this filing.